Cochrane · systematic review · CD006121
Whole brain radiation therapy (WBRT) alone versus WBRT and radiosurgery for the treatment of brain metastases
Patil, CG, Pricola, K, Sarmiento, JM, et al. · Cochrane Database of Systematic Reviews · 2017 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
5
current version
GRADE rated
5
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 1 · 20%Moderate 4 · 80%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Current version onlyWhole brain radiation therapy (WBRT) + stereotactic radiosurgery (SRS) versus WBRT for the treatment of brain metastases
Population: people with brain metastases
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Overall survival Whole brain radiation therapy (WBRT) + stereotactic radiosurgery (SRS) vs WBRT | HR 0.82 [0.65, 1.02] | 2 studies · 358 participants | Moderate Downgraded: imprecision |
Disease‐specific survival Whole brain radiation therapy (WBRT) + stereotactic radiosurgery (SRS) vs WBRT | RR 0.92 [0.64, 1.32] | 1 study · 286 participants | Moderate Downgraded: imprecision |
Local tumor control Whole brain radiation therapy (WBRT) + stereotactic radiosurgery (SRS) vs WBRT | HR 0.27 [0.14, 0.52] | 2 studies · 129 participants | Moderate Downgraded: imprecision |
Functionally independent survival (KPS) Whole brain radiation therapy (WBRT) + stereotactic radiosurgery (SRS) vs WBRT | RR 0.78 [0.61, 1] | 1 study · 145 participants | Moderate Downgraded: imprecision |
Steroid use Whole brain radiation therapy (WBRT) + stereotactic radiosurgery (SRS) vs WBRT | RR 0.64 [0.42, 0.97] | 1 study · 118 participants | Low Downgraded: imprecision |
Summary of findings table
Population: patients with the treatment of brain metastases
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Overall survival | HR 0.82 [0.65, 1.02] | 2 studies · 358 participants | Moderate Downgraded: imprecision |
Overall survival | HR 0.82 [0.65, 1.02] | 2 studies · 358 participants | Moderate Downgraded: imprecision |
Death owing to brain metastasis | RR 0.92 [0.64, 1.32] | 1 study · 286 participants | Moderate Downgraded: imprecision |
Local tumor control | HR 0.27 [0.14, 0.52] | 2 studies · 129 participants | Moderate Downgraded: imprecision |
Functionally independent survival (KPS) | RR 0.78 [0.61, 1] | 1 study · 145 participants | Moderate Downgraded: imprecision |
Steroid use | RR 0.64 [0.42, 0.97] | 1 study · 118 participants | Low Downgraded: imprecision |
SoF table
Population: patients with the treatment of brain metastases
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Overall Survival | HR 0.82 [0.65, 1.02] | 2 studies · 358 participants | Moderate Downgraded: imprecision |
Overall Survival | HR 0.82 [0.65, 1.02] | 2 studies · 358 participants | Moderate Downgraded: imprecision |
Death due to brain metastasis | RR 0.92 [0.64, 1.32] | 1 study · 286 participants | Moderate Downgraded: imprecision |
Local Tumor Control | HR 0.27 [0.14, 0.52] | 2 studies · 129 participants | Moderate Downgraded: imprecision |
Functionally Independent Survival (KPS) | RR 0.78 [0.61, 1] | 1 study · 145 participants | Moderate Downgraded: imprecision |
Steroid Use | RR 0.64 [0.42, 0.97] | 1 study · 118 participants | Low Downgraded: imprecision |